Zymeworks Total Liabilities 2016-2022 | ZYME

Zymeworks total liabilities from 2016 to 2022. Total liabilities can be defined as the total value of all possible claims against the corporation.
Zymeworks Annual Total Liabilities
(Millions of US $)
2021 $140
2020 $128
2019 $123
2018 $64
2017 $16
2016 $26
2015 $5
Zymeworks Quarterly Total Liabilities
(Millions of US $)
2022-03-31 $148
2021-12-31 $140
2021-09-30 $141
2021-06-30 $150
2021-03-31 $113
2020-12-31 $128
2020-09-30 $139
2020-06-30 $116
2020-03-31 $114
2019-12-31 $123
2019-09-30 $91
2019-06-30 $81
2019-03-31 $68
2018-12-31 $64
2018-09-30 $25
2018-06-30 $25
2018-03-31 $19
2017-12-31 $16
2017-09-30 $17
2017-06-30 $18
2017-03-31 $30
2016-12-31 $26
2016-09-30 $0
2016-06-30 $0
2016-03-31 $0
2015-12-31 $5
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.320B $0.027B
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00